22 October 2018 | News
Regeneron and Sanofi recognize that DUPIXENT can only help those uncontrolled moderate-to-severe AD patients that were prescribed the medicine if they can both access the medicine and use it properly.
Singapore - The FDA approves Regeneron Pharmaceuticals and development partner Sanofi's DUPIXENT (dupilumab) as add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
DUPIXENT is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in AD. DUPIXENT comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose. DUPIXENT can be used with or without topical corticosteroids. It should not be used in patients who are allergic to dupilumab or any of the ingredients in DUPIXENT.
It was originally approved in the U.S. in March 2017 for atopic dermatitis (eczema).